Equities Analysts Issue Forecasts for ELDN Q2 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Eledon Pharmaceuticals in a research note issued to investors on Wednesday, June 18th. HC Wainwright analyst Y. Chen expects that the company will earn ($0.31) per share for the quarter. HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Eledon Pharmaceuticals’ Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($0.97) EPS and FY2026 earnings at ($1.20) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN) last announced its earnings results on Wednesday, May 14th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.20.

Separately, Wall Street Zen cut Eledon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, June 6th.

Eledon Pharmaceuticals Price Performance

Shares of Eledon Pharmaceuticals stock opened at $2.75 on Monday. The business has a 50 day simple moving average of $3.02 and a two-hundred day simple moving average of $3.67. Eledon Pharmaceuticals has a 12 month low of $2.30 and a 12 month high of $5.54. The stock has a market capitalization of $164.67 million, a P/E ratio of -1.31 and a beta of -0.17.

Hedge Funds Weigh In On Eledon Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its holdings in shares of Eledon Pharmaceuticals by 418.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company’s stock valued at $33,000 after purchasing an additional 6,412 shares during the last quarter. CW Advisors LLC acquired a new stake in shares of Eledon Pharmaceuticals in the first quarter valued at approximately $34,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Eledon Pharmaceuticals in the first quarter valued at approximately $41,000. Alpine Global Management LLC acquired a new stake in shares of Eledon Pharmaceuticals in the fourth quarter valued at approximately $56,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Eledon Pharmaceuticals in the fourth quarter valued at approximately $66,000. Institutional investors and hedge funds own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).